Mark Alberts
Overview
Explore the profile of Mark Alberts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alberts M, He J, Kharat A, Pericone C, Ashton V
J Am Heart Assoc
. 2025 Jan;
14(2):e036401.
PMID: 39791405
Background: The economic burden of nonvalvular atrial fibrillation (NVAF) is substantial. Many patients with NVAF are obese and manage other health conditions requiring multiple medications. This real-world study compared health...
2.
Alberts M, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, et al.
Int J Clin Pharm
. 2023 May;
45(4):952-961.
PMID: 37204616
Background: Direct oral anticoagulants (DOACs) are the American Society of Hematology guideline-recommended treatment for venous thromboembolism (VTE) in the United States (US). Aim: To compare risk of VTE recurrence between...
3.
Alberts M, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, et al.
Adv Ther
. 2023 Mar;
40(5):2339-2354.
PMID: 36947331
Introduction: Direct oral anticoagulants (DOACs) are essential in ischemic stroke/systemic embolism (SE) prevention among patients with nonvalvular atrial fibrillation (NVAF). This study compared the risk of ischemic stroke/SE among patients...
4.
Alberts M, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, et al.
Adv Ther
. 2023 Feb;
40(4):1750-1764.
PMID: 36823479
Introduction: Among patients with venous thromboembolism (VTE), direct oral anticoagulants (DOACs) are recommended for preventing thromboembolic recurrence, complications, and mortality. This study compared the risk of VTE recurrence among patients...
5.
Krothapalli N, Patel S, Fayad M, Elmashad A, Killory B, Bruno C, et al.
World Neurosurg
. 2023 Jan;
173:e27-e36.
PMID: 36706981
Background: Early evidence suggests that middle meningeal artery (MMA) embolization is an efficacious minimally invasive neuroendovascular technique for the management of chronic subdural hematoma (cSDH). Particle and liquid embolic materials...
6.
Krothapalli N, Fayad M, Patel S, Elmashad A, Sussman E, Bruno C, et al.
Front Neurol
. 2022 Nov;
13:990722.
PMID: 36388232
Background: Trans-radial access (TRA) for MMA embolization has grown due to lower access site complications and greater patient satisfaction. Here, we describe the feasibility of utilizing a 6F Envoy Simmons...
7.
Hou Y, Elmashad A, Staff I, Alberts M, Nouh A
Front Neurol
. 2022 Jun;
13:860827.
PMID: 35655618
Introduction: Understanding the potential embolic source in young patients with ESUS may improve the diagnosis and treatment of such patients. Hypothesis: Potential embolic sources (PES) differ in young vs. older...
8.
Angiolillo D, Prats J, Deliargyris E, Schneider D, Scheiman J, Kimmelstiel C, et al.
Clin Pharmacokinet
. 2022 Jan;
61(4):465-479.
PMID: 35060092
Aspirin is one of the most widely used medicines. Although aspirin is commonly utilized for the treatment of several medical conditions, its broadest uptake is for the prevention of recurrent...
9.
Patel S, Topiwala K, Oliver F, Saber H, Panza G, Mui G, et al.
Stroke
. 2021 Sep;
52(12):3970-3977.
PMID: 34470494
Background And Purpose: Reversible cerebral vasoconstriction syndrome (RCVS) is a well-established cause of stroke, but its demographics and outcomes have not been well delineated. Methods: Analysis of the United States...
10.
Milentijevic D, Lin J, Chen Y, Kogan E, Shrivastava S, Sjoeland E, et al.
J Med Econ
. 2021 Jan;
24(1):212-217.
PMID: 33499689
Aims: Rivaroxaban reduces stroke compared with warfarin in patients with non-valvular atrial fibrillation (NVAF). This study compared healthcare costs before and after stroke in NVAF patients treated with rivaroxaban or...